Partnerships

We boldly pursue transformational licensing, acquisition, and collaboration opportunities that accelerate breakthrough innovation to prevent, treat and cure some of the world’s most challenging diseases, including those that have few or no effective treatments today. Our approach is rooted in trust and transparency, leading to long-term partnering success with a proven, positive track record of deal performance. These investments and collaborations continue to strengthen our pipeline with new, investigational assets like our targeted oral peptide, antibody drug conjugates (ADCs), next-generation chimeric antigen receptor (CAR) T-cell therapies, and with breakthrough innovations that have reached patients, including RYBREVANT, DARZALEX and CARVYKTI.